EHU131331
MISSION® esiRNA
targeting human PADI2
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
41105324
description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
AGACAAAGTGGGCGTGTTCTACGTGGAGAACCCGTTCTTCGGCCAACGCTATATCCACATCCTGGGCCGGCGGAAGCTCTACCATGTGGTCAAGTACACGGGTGGCTCCGCGGAGCTGCTGTTCTTCGTGGAAGGCCTCTGTTTCCCCGACGAGGGCTTCTCAGGCCTGGTCTCCATCCATGTCAGCCTGCTGGAGTACATGGCCCAGGACATTCCCCTGACTCCCATCTTCACGGACACCGTGATATTCCGGATTGCTCCGTGGATCATGACCCCCAACATCCTGCCTCCCGTGTCGGTGTTTGTGTGCTGCATGAAGGATAATTACCTGTTCCTGAAAGAGGTGAAGAACCTTGTGGAGAAAACCAACTGTGAGCTGAAGGTCTGCTTCCAGTACCTAAACCGAGGCGA
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... PADI2(11240)
General description
MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mehrdad Khajavi et al.
PLoS genetics, 13(6), e1006848-e1006848 (2017-06-16)
Recent findings indicate that growth factor-driven angiogenesis is markedly influenced by genetic variation. This variation in angiogenic responsiveness may alter the susceptibility to a number of angiogenesis-dependent diseases. Here, we utilized the genetic diversity available in common inbred mouse strains
Lin Wang et al.
Cancer research, 77(21), 5755-5768 (2017-08-19)
Onset of castration-resistance prostate cancer (CRPC) after long-term androgen deprivation therapy remains a major obstacle in the treatment of prostate cancer. The peptidylarginine deiminase PADI2 has been implicated in chronic inflammatory diseases and cancer. Here we show that
Global Trade Item Number
| SKU | GTIN |
|---|---|
| EHU131331-50UG | 04061828458165 |
| EHU131331-20UG | 04061828683307 |